Impact of TP53 and KRAS mutations on cisplatin-based...

Impact of TP53 and KRAS mutations on cisplatin-based adjuvant chemotherapy in non-small-cell lung cancer

X. Ma, E. Brambilla, J.C. Soria, A. Dunant, A.L. Vataire, P. Hainaut, the IALT-Bio study group

How much do you like this book?

What’s the quality of the file?

Download the book for quality assessment

What’s the quality of the downloaded files?

Volume:

Year:

2008

Language:

english

DOI:

10.1016/s1359-6349(08)71573-8

File:

PDF, 85 KB

english, 2008

Conversion to is in progress

Conversion to is failed